Position in ZTS
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$754,530
New position
Shares Held
10,500
first reported quarter
Ownership
0.003%
of shares outstanding
% of Portfolio
0.17%
of 13F equity value
Holder Rank
#701
of 1,408 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026HUSSMAN STRATEGIC ADVISORS, INC. holds $14,720,685 across 7 Drug Manufacturers - Specialty & Generic names. ZTS ranks #7 (5.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
27,300 | $4,601,142 | |
| 2 | ANIP |
Ani Pharmaceuticals Inc
|
31,500 | $2,607,570 | |
| 3 | ALKS |
Alkermes plc.
|
42,000 | $2,200,800 | |
| 4 | BCRX |
Biocryst Pharmaceuticals Inc
|
210,000 | $2,100,000 | |
| 5 | PAHC |
Phibro Animal Health Corp
|
42,000 | $1,318,800 | |
| 6 | UTHR |
UNITED THERAPEUTICS Corp
|
2,100 | $1,137,843 | |
| 7 | ZTS |
Zoetis Inc.
This page
|
10,500 | $754,530 |
All Filings in ZTS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $754,530 | 10,500 | Shares | Sole | 2026-08-03 | |
| No filing history on record for this holder in this stock. | ||||||